A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson¿s Disease
Clinical Trial Grant
Administered By
Neurology, Movement Disorders
Awarded By
Biogen, Inc.
Start Date
October 11, 2022
End Date
December 31, 2026
Administered By
Neurology, Movement Disorders
Awarded By
Biogen, Inc.
Start Date
October 11, 2022
End Date
December 31, 2026